Novartis announced that it is lowering its second-half sales prediction as a result of generic competition to key drugs. Novartis now looking at making strategic acquisitions and targeted investments, although the ideas are not disclosed. Nevertheless, the company will not be restricting its acquisition targets to companies in which it already holds a stake and there is nothing in its acquisition history to suggest it should.